ETS1

Summary

ETS1 (ETS proto-oncogene 1, transcription factor, HGNC:3488) is a protein-coding gene on chromosome 11q24.3, encoding Protein C-ets-1 (P14921). Transcription factor.

This gene encodes a member of the ETS family of transcription factors, which are defined by the presence of a conserved ETS DNA-binding domain that recognizes the core consensus DNA sequence GGAA/T in target genes. These proteins function either as transcriptional activators or repressors of numerous genes, and are involved in stem cell development, cell senescence and death, and tumorigenesis. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.

Source: NCBI Gene 2113 — RefSeq curated summary.

At a glance

• Gene–disease (curated): congenital heart disease (Moderate, ClinGen) — +3 more curated relationships
• GWAS associations: 107
• Clinical variants (ClinVar): 48 total — 1 pathogenic, 1 likely-pathogenic
• Phenotypes (HPO): 44
• Transcription factor: yes — 286 downstream targets (CollecTRI)
• MANE Select transcript: NM_001143820

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3488
Approved symbol	ETS1
Name	ETS proto-oncogene 1, transcription factor
Location	11q24.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10768, ETS-1
Ensembl gene	ENSG00000134954
Ensembl biotype	protein_coding
OMIM	164720
Entrez	2113

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 11 protein_coding, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000319397, ENST00000392668, ENST00000525404, ENST00000526145, ENST00000527676, ENST00000530924, ENST00000531611, ENST00000535549, ENST00000608978, ENST00000900294, ENST00000917570, ENST00000917571, ENST00000917572, ENST00000917573

RefSeq mRNA: 4 — MANE Select: NM_001143820 NM_001143820, NM_001162422, NM_001330451, NM_005238

CCDS: CCDS44767, CCDS53724, CCDS81648, CCDS8475

Canonical transcript exons

ENST00000392668 — 10 exons

Exon	Start	End
ENSE00000917323	128463509	128463627
ENSE00000917324	128480191	128480451
ENSE00000917325	128484823	128485071
ENSE00000917326	128486069	128486146
ENSE00000917327	128489290	128489490
ENSE00000917328	128490457	128490576
ENSE00002159982	128458765	128462576
ENSE00003590356	128556291	128556435
ENSE00003641042	128573062	128573144
ENSE00003705242	128587488	128587558

Expression profiles

Bgee: expression breadth ubiquitous, 263 present calls, max score 98.85.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 53.0774 / max 1288.4221, expressed in 1627 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
123095	43.0546	1597
123098	6.2552	1155
123099	1.8651	824
123104	0.8330	263
123088	0.3542	178
123096	0.2867	119
123097	0.2188	95
123106	0.1775	93
123105	0.0168	2
123103	0.0155	9

Top tissues by expression

291 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
visceral pleura	UBERON:0002401	98.85	gold quality
parietal pleura	UBERON:0002400	98.82	gold quality
tibia	UBERON:0000979	98.78	gold quality
epithelium of nasopharynx	UBERON:0001951	98.77	gold quality
lower lobe of lung	UBERON:0008949	98.71	gold quality
superficial temporal artery	UBERON:0001614	98.23	gold quality
colonic epithelium	UBERON:0000397	98.02	gold quality
pericardium	UBERON:0002407	97.94	gold quality
vena cava	UBERON:0004087	97.79	gold quality
lymph node	UBERON:0000029	97.49	gold quality
germinal epithelium of ovary	UBERON:0001304	97.47	gold quality
granulocyte	CL:0000094	97.29	gold quality
pleura	UBERON:0000977	96.80	gold quality
skin of hip	UBERON:0001554	96.68	gold quality
synovial joint	UBERON:0002217	96.65	gold quality
adipose tissue of abdominal region	UBERON:0007808	96.43	gold quality
omental fat pad	UBERON:0010414	96.39	gold quality
peritoneum	UBERON:0002358	96.37	gold quality
mucosa of paranasal sinus	UBERON:0005030	96.36	gold quality
gall bladder	UBERON:0002110	96.35	gold quality
saphenous vein	UBERON:0007318	96.29	gold quality
mammary duct	UBERON:0001765	96.21	gold quality
trabecular bone tissue	UBERON:0002483	96.20	gold quality
adipose tissue	UBERON:0001013	96.02	gold quality
amniotic fluid	UBERON:0000173	96.01	gold quality
spleen	UBERON:0002106	95.96	gold quality
connective tissue	UBERON:0002384	95.89	gold quality
subcutaneous adipose tissue	UBERON:0002190	95.67	gold quality
right lung	UBERON:0002167	95.40	gold quality
upper lobe of lung	UBERON:0008948	95.39	gold quality

Single-cell (SCXA)

Detected in 19 experiment(s), a significant marker in 16.

Experiment	Marker?	Max mean expression
E-MTAB-10553	yes	1339.19
E-CURD-112	yes	469.18
E-MTAB-8142	yes	126.04
E-MTAB-9221	yes	50.46
E-CURD-46	yes	45.34
E-CURD-122	yes	36.50
E-HCAD-10	yes	31.72
E-CURD-88	yes	31.54
E-CURD-119	yes	27.76
E-MTAB-8410	yes	27.00
E-MTAB-8271	yes	15.57
E-ANND-3	yes	15.16
E-MTAB-9543	yes	14.45
E-GEOD-130148	yes	7.32
E-MTAB-9067	yes	5.18

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

286 targets.

Target	Regulation
ABCB1	Activation
ABCC1	Unknown
ACE	Unknown
ADAM2
AKR1B10	Activation
ALG12
ANG	Unknown
ANGPT2	Activation
ANPEP	Activation
ARHGDIB	Unknown
ASAP1	Unknown
ATP11C
ATP2A3	Activation
ATXN2	Unknown
B3GAT3	Unknown
B4GALT1
B4GALT5
BAX	Repression
BCL2	Unknown
BCL2L1	Unknown
BID	Unknown
BIRC2	Unknown
BIRC3
BMP4	Activation
C3AR1	Activation
CA9	Repression
CASP1	Activation
CASP3	Activation
CASP8	Activation
CAT

JASPAR motifs

Motif	Name	Family
MA0098.1	ETS1	Ets-related
MA0098.3	ETS1	Ets-related
MA0098.4	ETS1	Ets-related

JASPAR matrix evidence (PMIDs): PMID:1542566, PMID:20517297

Upstream regulators (CollecTRI, top): AP1, DAXX, ETS1, ETS2, ETV4, ETV7, FOS, GLI3, HIF1A, JUN, NFE2L2, NFKB, NR3C1, POU2F1, POU2F2, RARA, RXRA, SP100, SP1, TFAP2A, TOX2, TP53, WT1, XRCC5

miRNA regulators (miRDB)

246 targeting ETS1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-3924	100.00	72.09	2394
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-3148	99.97	75.06	6478

Literature-anchored findings (GeneRIF, showing 40)

• Hepatocyte growth factor induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line. (PMID:11830328)
• c-Ets1 expression in epithelial ovarian cancer correlates to the malignant potential of the tumor. (PMID:11836635)
• Sp100 interacts with ETS-1 and stimulates its transcriptional activity. (PMID:11909962)
• Epidermal growth factor-mediated activation of the ETS domain transcription factor Elk-1 requires nuclear calcium (PMID:11971908)
• cooperatively binds to the palindromic head to head ETS-binding sites of the stromelysin-1 promoter by counteracting autoinhibition (PMID:12034715)
• Coexpression of P-glycoprotein, Ets-1, and p53 in oral carcinoma is associated with poor prognosis (PMID:12073053)
• results showed a significant correlation between microvessel counts and ets-1 gene expression levels in uterine cervical cancers;localization of ETS-1 was similar to that of vascular endothelial cells (PMID:12377648)
• results showed a significant correlation between microvessel count and ets-1 gene expression levels in uterine endometrial cancers; localization of ETS-1 was similar to that of vascular endothelial cells (PMID:12377649)
• HIF-2alpha and Ets-1 binding is required for transcriptional activation of Flk-1 in endothelial cells (PMID:12464608)
• Its expression is an independent prognostic marker for relapse-free survival in breast cancer (PMID:12466970)
• ETS1 phosphorylation by CAMKII is regulated in a pathway with calcium and GM-CSF (PMID:12475968)
• ETS1 may be regulated by PKCalpha in invasive breast cancer cells (PMID:12632071)
• a splicing variant of Ets1 is downregulated in invasive Ets1-expressing breast cancer cells (PMID:12632078)
• interacts with EAPII and modulates its transcriptional function (PMID:12743594)
• AP-2alpha gene expression in the placenta is enhanced by a cis-acting element at nucleotides -1279 to -1139 that contains a critical Ets1-binding site. (PMID:12843180)
• findings suggest a potential mechanism by which PTHrP transcription may be regulated by Ets-1 as a consequence of events that promote tumorigenic behavior in breast epithelial cells (PMID:12850290)
• Ets-1 expression may be an important pathogenic mechanism and predictor of aggressive biologic behavior of cutaneous melanoma (PMID:12920221)
• ets-1 together with microvessel density determined by CD105 may have prognostic value in the multistep event of carcinogenesis. (PMID:12932931)
• Upregulation of Ets 1 transcription factor ia assiciated with neoplasm invasiveness in Hereditary nonpolyposis colorectal cancers (PMID:12949792)
• overexpression of ETS-1 is associated with angiogenesis and ovarian cancer progression (PMID:12967474)
• binding of ETS transcription factors to the ETS binding sites in the human LIF promoter is critical for its inducibility in response to T cell activators and play an important functional role within the endocrine-immune network. (PMID:14557674)
• p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. (PMID:14586398)
• Ets-1 is involved in transcriptional regulation of factors involved in invasion of melanoma cells. (PMID:14704859)
• Ets-1 expression is increased in asthma and contributes to enhanced expression of TNF-alpha-induced matrix metalloproteinase-9 and tenascin in bronchial fibroblasts activated ex vivo. (PMID:14734780)
• a novel, functional binding element in the proximal region of the TN-C promoter mediating responsiveness to TGF-beta involving Smad3/4, Sp1, Ets1, and CBP/p300 (PMID:15001984)
• Data suggest that glycogen synthase kinase-3beta-phosphorylated Ets1 is a target of Runx1-recruited calcineurin phosphatase at the granulocyte macrophage colony-stimulating factor promoter. (PMID:15123671)
• Ets-1 regulated angiogenesis through the induction of angiogenic growth factors (VEGF and HGF). (PMID:15173033)
• SP100 modulates ETS1-dependent biological processes (PMID:15247905)
• ETS-1 in ovarian endometriomas is significantly positively correlated with microvessel counts. (PMID:15302318)
• Protein kinase C is a potential regulator of Ets1 activity in breast cancer cells. (PMID:15389378)
• proximal 5’-flanking region of the IKKalpha gene contains a functional promoter reciprocally regulated by p53 and ETS-1 (PMID:15469934)
• Ets1 serves as an effector for protein kinase C alpha to fulfil certain functions in cancer ce (PMID:15531915)
• Interleukins 2 and 15 regulate Ets1 expression via ERK1/2 and MNK1 in human natural killer cells (PMID:15563472)
• Ras/mitogen-activated protein kinase signaling activates ETS-1 by CBPp300 recruitment. (PMID:15572696)
• Ets-1 has a role in breast tumor growth and spread [review] (PMID:15574387)
• Associated with tumour growth and histological differentiation of breast carcinomas. (PMID:15578430)
• Genes that are negatively regulated by ETS1 and upregulated by SP100 have antimigratory or antiangiogenic properties. (PMID:15592518)
• Results suggest that Ets-1 might play an important role in carcinogenesis and/or the progression of human prostatic carcinomas. (PMID:15693893)
• Ets1 is activated in human adrenocortical cells expressing a mutated K-ras gene. (PMID:15699632)
• Modification of local protooncogene Ets-1 level is likely being involved in the regulation of melanoma growth (PMID:15848191)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	ets1	ENSDARG00000024431
mus_musculus	Ets1	ENSMUSG00000032035
rattus_norvegicus	Ets1	ENSRNOG00000008941

Paralogs (28): ETV1 (ENSG00000006468), ETV7 (ENSG00000010030), SPI1 (ENSG00000066336), ELF4 (ENSG00000102034), ETV2 (ENSG00000105672), ERF (ENSG00000105722), ELF2 (ENSG00000109381), ELK3 (ENSG00000111145), ETV3 (ENSG00000117036), ELF1 (ENSG00000120690), SPDEF (ENSG00000124664), ELK1 (ENSG00000126767), EHF (ENSG00000135373), ELF5 (ENSG00000135374), ETV6 (ENSG00000139083), FLI1 (ENSG00000151702), GABPA (ENSG00000154727), ERG (ENSG00000157554), ETS2 (ENSG00000157557), ELK4 (ENSG00000158711), ELF3 (ENSG00000163435), FEV (ENSG00000163497), SPIC (ENSG00000166211), ETV4 (ENSG00000175832), ETV5 (ENSG00000244405), ETV3L (ENSG00000253831), ERFL (ENSG00000268041), SPIB (ENSG00000269404)

Protein

Protein identifiers

Protein C-ets-1 — P14921 (reviewed: P14921)

Alternative names: p54

All UniProt accessions (2): P14921, V9GYD6

UniProt curated annotations — full annotation on UniProt →

Function. Transcription factor. Directly controls the expression of cytokine and chemokine genes in a wide variety of different cellular contexts. May control the differentiation, survival and proliferation of lymphoid cells. May also regulate angiogenesis through regulation of expression of genes controlling endothelial cell migration and invasion. Acts as a dominant-negative for isoform c-ETS-1A.

Subunit / interactions. Binds DNA as a homodimer; homodimerization is required for transcription activation. Interacts with MAF and MAFB. Interacts with PAX5; the interaction alters DNA-binding properties. Interacts with DAXX. Interacts with UBE2I. Interacts with SP100; the interaction is direct and modulates ETS1 transcriptional activity.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Highly expressed within lymphoid cells. Isoforms c-ETS-1A and Ets-1 p27 are both detected in all fetal tissues tested, but vary with tissue type in adult tissues. None is detected in brain or kidney.

Post-translational modifications. Sumoylated on Lys-15 and Lys-227, preferentially with SUMO2; which inhibits transcriptional activity. Ubiquitinated; which induces proteasomal degradation. Phosphorylation at Ser-251, Ser-282 and Ser-285 by CaMK2/CaMKII in response to calcium signaling decreases affinity for DNA: an increasing number of phosphoserines causes DNA-binding to become progressively weaker.

Activity regulation. Autoinhibited by a module composed of four alpha helices (HI-1, HI-2, H4, and H5) that flank the DNA-binding ETS domain, reducing the affinity for DNA. Phosphorylation by CaMK2/CaMKII in response to calcium signaling decreases affinity for DNA.

Induction. Up-regulated by retinoic acid, VEGF, TNF/TNFA, lipopolysaccharide and in response to hypoxia (at protein level).

Similarity. Belongs to the ETS family.

Isoforms (5)

UniProt ID	Names	Canonical?
P14921-1	c-ETS-1A, Ets-1 p51	yes
P14921-2	c-ETS-1B, Ets-1 p42
P14921-3	3
P14921-4	Ets-1 p27, Ets-1Delta(III-VI)
P14921-5	5

RefSeq proteins (4): NP_001137292, NP_001155894, NP_001317380, NP_005229 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000418	Ets_dom	Domain
IPR003118	Pointed_dom	Domain
IPR013761	SAM/pointed_sf	Homologous_superfamily
IPR016311	Transform_prot_C-ets	Family
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR041886	SAM_PNT-ETS-1	Domain
IPR045688	Ets1_N_flank	Domain
IPR046328	ETS_fam	Family

Pfam: PF00178, PF02198, PF19525

UniProt features (49 total): modified residue 12, helix 8, strand 6, splice variant 5, region of interest 5, cross-link 4, sequence conflict 4, turn 2, chain 1, domain 1, DNA-binding region 1

Structure

Experimental structures (PDB)

21 structures.

PDB	Method	Resolution (Å)
1GVJ	X-RAY DIFFRACTION	1.53
4LG0	X-RAY DIFFRACTION	2.19
4L18	X-RAY DIFFRACTION	2.3
3WTS	X-RAY DIFFRACTION	2.35
3WTT	X-RAY DIFFRACTION	2.35
3WU1	X-RAY DIFFRACTION	2.4
4L0Y	X-RAY DIFFRACTION	2.5
2NNY	X-RAY DIFFRACTION	2.58
3WU0	X-RAY DIFFRACTION	2.6
3WTZ	X-RAY DIFFRACTION	2.61
3WTU	X-RAY DIFFRACTION	2.7
3WTV	X-RAY DIFFRACTION	2.7
3WTY	X-RAY DIFFRACTION	2.7
4L0Z	X-RAY DIFFRACTION	2.7
3WTX	X-RAY DIFFRACTION	2.8
3WTW	X-RAY DIFFRACTION	2.9
5ZMC	X-RAY DIFFRACTION	2.99
3MFK	X-RAY DIFFRACTION	3
3RI4	X-RAY DIFFRACTION	3
2STT	SOLUTION NMR
2STW	SOLUTION NMR

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P14921-F1	65.95	0.32

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (16): 38, 223, 251, 254, 265, 267, 270, 282, 285, 305, 8, 15, 138, 227, 8, 15

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-2559585	Oncogene Induced Senescence
R-HSA-9976102	Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)

MSigDB gene sets: 625 (showing top): PID_BCR_5PATHWAY, GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_UP, GOBP_MYELOID_CELL_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_ERYTHROCYTE_DIFFERENTIATION, GOBP_MYELOID_CELL_HOMEOSTASIS, GOBP_INFLAMMATORY_RESPONSE, TTTGTAG_MIR520D, GOBP_ERYTHROCYTE_HOMEOSTASIS, GOBP_POSITIVE_REGULATION_OF_VASCULATURE_DEVELOPMENT, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, KEGG_DORSO_VENTRAL_AXIS_FORMATION, TURJANSKI_MAPK7_TARGETS, MCBRYAN_PUBERTAL_TGFB1_TARGETS_UP, MCBRYAN_TERMINAL_END_BUD_DN, CAGCTG_AP4_Q5

GO Biological Process (23): regulation of transcription by RNA polymerase II (GO:0006357), transcription by RNA polymerase II (GO:0006366), immune response (GO:0006955), negative regulation of cell population proliferation (GO:0008285), positive regulation of endothelial cell migration (GO:0010595), positive regulation of gene expression (GO:0010628), cell differentiation (GO:0030154), PML body organization (GO:0030578), regulation of apoptotic process (GO:0042981), positive regulation of blood vessel endothelial cell migration (GO:0043536), positive regulation of erythrocyte differentiation (GO:0045648), regulation of angiogenesis (GO:0045765), positive regulation of angiogenesis (GO:0045766), negative regulation of cell cycle (GO:0045786), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), response to antibiotic (GO:0046677), cell motility (GO:0048870), positive regulation of inflammatory response (GO:0050729), positive regulation of miRNA transcription (GO:1902895), positive regulation of leukocyte adhesion to vascular endothelial cell (GO:1904996), immune system process (GO:0002376), regulation of DNA-templated transcription (GO:0006355)

GO Molecular Function (13): transcription cis-regulatory region binding (GO:0000976), RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), transcription corepressor binding (GO:0001222), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), nucleic acid binding (GO:0003676), DNA binding (GO:0003677), DNA-binding transcription factor activity (GO:0003700), identical protein binding (GO:0042802), RNA polymerase II-specific DNA-binding transcription factor binding (GO:0061629), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565), sequence-specific double-stranded DNA binding (GO:1990837)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Cellular Senescence	1
Differentiation of T cells	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
cellular anatomical structure	3
transcription by RNA polymerase II	2
DNA-templated transcription	2
negative regulation of cellular process	2
angiogenesis	2
regulation of transcription by RNA polymerase II	2
positive regulation of DNA-templated transcription	2
binding	2
immune system process	1
response to stimulus	1
cell population proliferation	1
regulation of cell population proliferation	1
regulation of endothelial cell migration	1
positive regulation of cell migration	1
endothelial cell migration	1
gene expression	1
regulation of gene expression	1
positive regulation of macromolecule biosynthetic process	1
cellular developmental process	1
nuclear body organization	1
apoptotic process	1
regulation of programmed cell death	1
positive regulation of endothelial cell migration	1
blood vessel endothelial cell migration	1
regulation of blood vessel endothelial cell migration	1
erythrocyte differentiation	1
positive regulation of myeloid cell differentiation	1
regulation of erythrocyte differentiation	1
regulation of anatomical structure morphogenesis	1
regulation of vasculature development	1
regulation of angiogenesis	1
positive regulation of vasculature development	1
cell cycle	1
regulation of cell cycle	1
positive regulation of RNA biosynthetic process	1
response to chemical	1
cellular process	1
inflammatory response	1

Protein interactions and networks

STRING

3484 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ETS1	RUNX1	Q01196	992
ETS1	PAX5	Q02548	958
ETS1	TP53	P04637	925
ETS1	EP300	Q09472	914
ETS1	GATA3	P23771	902
ETS1	MAFB	Q9Y5Q3	870
ETS1	TBX21	Q9UL17	862
ETS1	STAT5B	P51692	836
ETS1	GATA1	P15976	831
ETS1	MAPK1	P28482	820
ETS1	CREB1	P16220	815
ETS1	FOXO1	Q12778	812
ETS1	CEBPA	P49715	802
ETS1	JUN	P05412	762
ETS1	FOS	P01100	733

IntAct

108 interactions, top by confidence:

A	B	Type	Score
SRSF11	ETS1	psi-mi:“MI:0915”(physical association)	0.570
ETS1	NFKB1	psi-mi:“MI:0915”(physical association)	0.540
ETS1	NFKB1	psi-mi:“MI:2364”(proximity)	0.540
MAPK1	ETS1	psi-mi:“MI:2364”(proximity)	0.530
ETS1	MAPK1	psi-mi:“MI:0914”(association)	0.530
ETS1	MAPK1	psi-mi:“MI:2364”(proximity)	0.530
ETS1	ARID4B	psi-mi:“MI:0915”(physical association)	0.520
EIF5B	ETS1	psi-mi:“MI:0915”(physical association)	0.520
JUN	ETS1	psi-mi:“MI:0915”(physical association)	0.520
ETS1	CYBC1	psi-mi:“MI:0915”(physical association)	0.520
CYBC1	ETS1	psi-mi:“MI:0915”(physical association)	0.520
PRKDC	ETS1	psi-mi:“MI:0407”(direct interaction)	0.520
ETS1	SP100	psi-mi:“MI:0915”(physical association)	0.510
SP100	ETS1	psi-mi:“MI:0915”(physical association)	0.510
ETS1	ETS1	psi-mi:“MI:0915”(physical association)	0.500
ETS1	ETS1	psi-mi:“MI:0914”(association)	0.500
TAL1	ETS1	psi-mi:“MI:0914”(association)	0.500
ETS1	TAL1	psi-mi:“MI:0915”(physical association)	0.500
TLX1	ETS1	psi-mi:“MI:0915”(physical association)	0.460
TLX3	ETS1	psi-mi:“MI:0915”(physical association)	0.460
ETS1	TLX1	psi-mi:“MI:0403”(colocalization)	0.460
ETS1	TLX3	psi-mi:“MI:0403”(colocalization)	0.460
TLX3	ETS1	psi-mi:“MI:0403”(colocalization)	0.460
ETS1	AR	psi-mi:“MI:2364”(proximity)	0.450
ETS1	AR	psi-mi:“MI:0403”(colocalization)	0.450
AR	ETS1	psi-mi:“MI:0403”(colocalization)	0.450

BioGRID (137): ETS1 (Affinity Capture-Western), ETS1 (Affinity Capture-Western), DAXX (Two-hybrid), ETS1 (Affinity Capture-Western), ETS1 (Affinity Capture-MS), ETS1 (Affinity Capture-Western), ZBTB7A (Affinity Capture-Western), TP53 (Affinity Capture-Western), MAPK1 (Co-localization), AR (Co-localization), NFKB1 (Co-localization), SMAD3 (Co-localization), PKM (Affinity Capture-MS), CHI3L2 (Affinity Capture-MS), THUMPD1 (Affinity Capture-MS)

ESM2 similar proteins: A1A4L6, F1QDF8, O35914, O75113, O95238, P01105, P10157, P13474, P14921, P15036, P15037, P15062, P15375, P18755, P18756, P19102, P19335, P27577, P40649, P41156, P78545, Q28EW4, Q28F43, Q32NH9, Q3MHT3, Q3UM89, Q3UPW2, Q3YFL6, Q4G112, Q4V7E1, Q5M7N6, Q5SW75, Q66IG8, Q6IE24, Q6NRK3, Q6PUR7, Q708W1, Q708W2, Q76I76, Q7M6U3

Diamond homologs: A0A1W2PQ73, A0JN51, A1A4L6, A1YF15, A1YG61, A1YG91, A2D4Z7, A2T737, A2T762, A3FEM2, A4GTP4, A8WFJ9, O00321, O01519, O70132, O70273, O95238, P01105, P10157, P11308, P11536, P13474, P14921, P15036, P15037, P15062, P18755, P18756, P19102, P19419, P20105, P26323, P27577, P28322, P28324, P29773, P29774, P29775, P29776, P32519

SIGNOR signaling

35 interactions.

A	Effect	B	Mechanism
MAPK3	up-regulates	ETS1	phosphorylation
ETS1	“up-regulates quantity by expression”	ITGA11
ETS1	“up-regulates quantity by expression”	VWF	“transcriptional regulation”
ETS1	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
ETS1	“up-regulates quantity by expression”	CD8A	“transcriptional regulation”
ETS1	“up-regulates quantity by expression”	ECE1	“transcriptional regulation”
ETS1	“up-regulates quantity by expression”	GP6	“transcriptional regulation”
ETS1	“up-regulates quantity by expression”	MMP9	“transcriptional regulation”
ETS1	“up-regulates quantity by expression”	MMP13	“transcriptional regulation”
ETS1	“up-regulates quantity by expression”	SLC26A3	“transcriptional regulation”
TP53	“down-regulates activity”	ETS1	binding
ETS1	“up-regulates quantity by expression”	TBXAS1	“transcriptional regulation”
ETS1	“up-regulates quantity by expression”	MUC4	“transcriptional regulation”
GFI1	“down-regulates activity”	ETS1	binding
ETS1	“down-regulates activity”	GFI1	binding
ETS1	“down-regulates quantity by repression”	BAX	“transcriptional regulation”
ETS1	“up-regulates quantity”	FOS	“transcriptional regulation”
TLX1	“down-regulates activity”	ETS1	binding
TLX3	“down-regulates activity”	ETS1	binding
ETS1	up-regulates	Apoptosis
ETS1	“up-regulates quantity by expression”	TNC	“transcriptional regulation”
ETS1	“up-regulates quantity by expression”	TBX22	“transcriptional regulation”
GSK3B	“up-regulates quantity by stabilization”	ETS1	phosphorylation
MAF	down-regulates	ETS1	binding
MAPK7	up-regulates	ETS1	phosphorylation
CAMK2A	down-regulates	ETS1	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 73 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
transcription by RNA polymerase II	7	7.7×	5e-03
negative regulation of cell population proliferation	9	5.9×	5e-03

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	29
Likely benign	3
Benign	5

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
627517	NM_001143820.2(ETS1):c.1044_1049delinsTT (p.Lys349fs)	Pathogenic
1333667	NM_001143820.2(ETS1):c.103C>T (p.Arg35Ter)	Likely pathogenic

SpliceAI

1303 predictions. Top by Δscore:

Variant	Effect	Δscore
11:128462576:CCTGA:C	acceptor_loss	1.0000
11:128462577:CTG:C	acceptor_loss	1.0000
11:128463503:CCTTA:C	donor_loss	1.0000
11:128463504:CTTA:C	donor_loss	1.0000
11:128463505:TTAC:T	donor_loss	1.0000
11:128463506:TA:T	donor_loss	1.0000
11:128463507:A:C	donor_loss	1.0000
11:128463624:CTGC:C	acceptor_gain	1.0000
11:128463625:TGC:T	acceptor_gain	1.0000
11:128463626:GCCTA:G	acceptor_loss	1.0000
11:128463627:CCTAG:C	acceptor_loss	1.0000
11:128463628:C:CC	acceptor_gain	1.0000
11:128463628:CTAG:C	acceptor_loss	1.0000
11:128463629:T:C	acceptor_loss	1.0000
11:128463711:C:A	donor_gain	1.0000
11:128484818:CCT:C	donor_loss	1.0000
11:128484819:CTAC:C	donor_loss	1.0000
11:128484821:A:AC	donor_gain	1.0000
11:128484822:C:CC	donor_gain	1.0000
11:128484822:CCA:C	donor_gain	1.0000
11:128484867:T:TA	donor_gain	1.0000
11:128485067:ATAGC:A	acceptor_gain	1.0000
11:128485068:TAGC:T	acceptor_gain	1.0000
11:128485069:AGC:A	acceptor_gain	1.0000
11:128485070:GC:G	acceptor_gain	1.0000
11:128485071:CC:C	acceptor_gain	1.0000
11:128485072:C:CC	acceptor_gain	1.0000
11:128485073:T:A	acceptor_loss	1.0000
11:128485079:C:CT	acceptor_gain	1.0000
11:128485080:A:T	acceptor_gain	1.0000

AlphaMissense

3225 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:128462399:G:C	H430D	1.000
11:128462401:A:G	L429P	1.000
11:128462419:C:T	G423E	1.000
11:128462420:C:A	G423W	1.000
11:128462422:A:G	L422P	1.000
11:128462425:A:G	L421P	1.000
11:128462434:A:G	L418P	1.000
11:128462434:A:T	L418Q	1.000
11:128462439:A:C	C416W	1.000
11:128462440:C:T	C416Y	1.000
11:128462441:A:G	C416R	1.000
11:128462445:A:C	F414L	1.000
11:128462445:A:T	F414L	1.000
11:128462446:A:C	F414C	1.000
11:128462446:A:G	F414S	1.000
11:128462447:A:C	F414V	1.000
11:128462447:A:G	F414L	1.000
11:128462447:A:T	F414I	1.000
11:128462449:C:G	R413P	1.000
11:128462450:G:T	R413S	1.000
11:128462452:T:C	Y412C	1.000
11:128462453:A:C	Y412D	1.000
11:128462453:A:G	Y412H	1.000
11:128462453:A:T	Y412N	1.000
11:128462455:A:T	V411E	1.000
11:128462456:C:T	V411M	1.000
11:128462458:T:C	Y410C	1.000
11:128462458:T:G	Y410S	1.000
11:128462459:A:C	Y410D	1.000
11:128462459:A:G	Y410H	1.000

dbSNP variants (sampled 300 via entrez): RS1000116887 (11:128536929 A>G), RS1000128482 (11:128578239 T>C), RS1000144563 (11:128533956 A>G), RS1000158303 (11:128574808 T>G), RS1000175669 (11:128473531 C>G,T), RS1000212773 (11:128560412 C>A,G,T), RS1000213054 (11:128569929 T>C,G), RS1000218068 (11:128520625 C>T), RS1000322906 (11:128509462 A>G), RS1000323372 (11:128554302 T>A), RS1000325576 (11:128522424 C>A,G,T), RS1000346614 (11:128529624 G>A), RS1000357516 (11:128463024 T>A), RS1000369810 (11:128469172 C>G), RS1000393621 (11:128566386 C>T)

Disease associations

OMIM: gene MIM:164720 | disease phenotypes: MIM:147791

GenCC curated gene-disease

Disease	Classification	Inheritance
congenital heart disease	Moderate	Autosomal dominant
systemic lupus erythematosus	Supportive	Unknown
neurodevelopmental disorder	Limited	Autosomal dominant
Tourette syndrome	No Known Disease Relationship	Unknown

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
congenital heart disease	Moderate	AD

Mondo (5): Jacobsen syndrome (MONDO:0007838), congenital heart disease (MONDO:0005453), Tourette syndrome (MONDO:0007661), systemic lupus erythematosus (MONDO:0007915), neurodevelopmental disorder (MONDO:0700092)

Orphanet (1): Jacobsen syndrome (Orphanet:2308)

HPO phenotypes

44 total (30 of 44 shown, HPO-id order):

HPO	Term
HP:0000093	Proteinuria
HP:0000155	Oral ulcer
HP:0000488	Retinopathy
HP:0000716	Depression
HP:0000790	Hematuria
HP:0000822	Hypertension
HP:0000992	Cutaneous photosensitivity
HP:0001250	Seizure
HP:0001369	Arthritis
HP:0001596	Alopecia
HP:0001824	Weight loss
HP:0001873	Thrombocytopenia
HP:0001878	Hemolytic anemia
HP:0001882	Decreased total leukocyte count
HP:0001945	Fever
HP:0002039	Anorexia
HP:0002072	Chorea
HP:0002716	Lymphadenopathy
HP:0003453	Antineutrophil antibody positivity
HP:0003493	Antinuclear antibody positivity
HP:0005421	Decreased circulating complement C3 concentration
HP:0005764	Polyarticular arthritis
HP:0007417	Discoid lupus rash
HP:0012085	Pyuria
HP:0012378	Fatigue
HP:0020151	Anti-dsDNA antibody positivity
HP:0025300	Malar rash
HP:0030880	Raynaud phenomenon
HP:0032235	Anti-La/SS-B antibody positivity
HP:0033028	Anti-U1 ribonucleoprotein antibody positivity

GWAS associations

107 associations (top):

Study	Trait	p-value
GCST000507_5	Systemic lupus erythematosus	2.000000e-25
GCST000592_1	Systemic lupus erythematosus	2.000000e-11
GCST000612_26	Celiac disease	5.000000e-16
GCST001454_10	Rheumatoid arthritis	8.000000e-07
GCST001762_171	Obesity-related traits	8.000000e-06
GCST001795_26	Systemic lupus erythematosus	3.000000e-08
GCST002083_4	Self-reported allergy	6.000000e-07
GCST002318_104	Rheumatoid arthritis	1.000000e-10
GCST002318_105	Rheumatoid arthritis	1.000000e-06
GCST002318_106	Rheumatoid arthritis	4.000000e-06
GCST002643_3	Follicular lymphoma	7.000000e-11
GCST002874_57	Psoriasis	2.000000e-09
GCST002874_58	Psoriasis	3.000000e-06
GCST002874_59	Psoriasis	3.000000e-06
GCST002874_63	Psoriasis	7.000000e-06
GCST002874_65	Psoriasis	1.000000e-08
GCST002932_26	Manganese levels	2.000000e-06
GCST003090_7	Depressive and manic episodes in bipolar disorder	7.000000e-06
GCST003091_6	Depressive episodes in bipolar disorder	3.000000e-06
GCST003155_14	Systemic lupus erythematosus	1.000000e-10
GCST003156_32	Systemic lupus erythematosus	2.000000e-08
GCST003184_16	Atopic dermatitis	1.000000e-20
GCST003184_8	Atopic dermatitis	2.000000e-18
GCST003268_28	Psoriasis vulgaris	1.000000e-07
GCST003599_18	Systemic lupus erythematosus	7.000000e-12
GCST003622_38	Systemic lupus erythematosus	1.000000e-06
GCST004131_65	Inflammatory bowel disease	2.000000e-08
GCST004133_43	Ulcerative colitis	6.000000e-06
GCST004603_71	Platelet count	6.000000e-18
GCST004607_37	Plateletcrit	6.000000e-17

EFO canonical traits (24, from GWAS)

EFO ID	Trait name
EFO:0007704	depressive episode measurement
EFO:0007705	manic episode measurement
EFO:1001494	psoriasis vulgaris
EFO:0004309	platelet count
EFO:0007985	platelet crit
EFO:0004833	neutrophil count
EFO:0004842	eosinophil count
EFO:0007987	granulocyte count
EFO:0005090	basophil count
EFO:0005091	monocyte count
EFO:0004587	lymphocyte count
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0008377	mosquito bite reaction itch intensity measurement
EFO:0008378	mosquito bite reaction size measurement
EFO:0004695	intraocular pressure measurement
EFO:0005128	albumin:globulin ratio measurement
EFO:0004312	vital capacity
EFO:0009933	Thyroid preparation use measurement
EFO:0009658	adverse effect
EFO:0004847	age at onset
EFO:0004530	triglyceride measurement
EFO:0004531	urate measurement
EFO:0007991	eosinophil percentage of leukocytes
EFO:0007990	neutrophil percentage of leukocytes

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D006330	Heart Defects, Congenital	C14.240.400; C14.280.400; C16.131.240.400
D008180	Lupus Erythematosus, Systemic	C17.300.480; C20.111.590
D065886	Neurodevelopmental Disorders	F03.625
D005879	Tourette Syndrome	C10.228.140.079.898; C10.228.662.825.800; C10.574.500.850; C16.320.400.820; F03.625.992.850

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

109 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases methylation	9
Particulate Matter	affects cotreatment, increases expression, decreases expression, decreases reaction, increases abundance (+1 more)	4
trichostatin A	affects cotreatment, increases expression	3
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	3
Copper	affects binding, affects expression, increases expression	3
Cyclosporine	decreases expression, increases expression	3
methylmercuric chloride	increases expression	2
bisphenol A	decreases expression, decreases methylation	2
mercuric bromide	increases expression, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
Vorinostat	affects cotreatment, increases expression	2
Panobinostat	affects cotreatment, increases expression	2
Estradiol	affects cotreatment, increases expression, decreases expression	2
Fluorouracil	increases expression, affects reaction, decreases expression	2
Hydrogen Peroxide	decreases expression, decreases reaction, increases reaction, affects expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Silicon Dioxide	increases expression	2
Tobacco Smoke Pollution	decreases methylation, increases expression	2
Aflatoxin B1	decreases methylation, increases expression	2
Cadmium Chloride	increases abundance, increases expression, decreases expression	2
aristolochic acid I	decreases expression	1
TAK-243	increases sumoylation	1
geldanamycin	increases expression	1
apocarotenal	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenate	increases abundance, increases expression	1
beta-lapachone	increases expression	1
arsenite	affects binding, increases reaction, increases expression, decreases reaction, decreases expression	1
sodium arsenite	increases expression	1
benzo(k)fluoranthene	decreases reaction, increases expression	1

Cellosaurus cell lines

10 cell lines: 7 cancer cell line, 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A1M2	SEES3-1V human ETS1, clone1	Embryonic stem cell	Male
CVCL_A1M3	SEES3-1V human ETS1, clone2	Embryonic stem cell	Male
CVCL_A1M4	SEES3-1V human ETS1, clone3	Embryonic stem cell	Male
CVCL_B8FM	Abcam HCT 116 ETS1 KO	Cancer cell line	Male
CVCL_B8VH	Abcam MCF-7 ETS1 KO	Cancer cell line	Female
CVCL_B9HV	Abcam A-549 ETS1 KO	Cancer cell line	Male
CVCL_E1WL	HAP1 ETS1 (-) 1	Cancer cell line	Male
CVCL_E1WM	HAP1 ETS1 (-) 2	Cancer cell line	Male
CVCL_E1WN	HAP1 ETS1 (-) 3	Cancer cell line	Male
CVCL_E1WP	HAP1 ETS1 (-) 4	Cancer cell line	Male

Clinical trials (associated diseases)

301 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00668824	PHASE4	UNKNOWN	Improved Diagnosis of Congenital Heart Disease by Magnetic Resonance Imaging Using Vasovist
NCT01368705	PHASE4	COMPLETED	Nitrogen Balance in Infants After Post Cardiothoracic Surgery
NCT01619982	PHASE4	COMPLETED	Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
NCT02122679	PHASE4	WITHDRAWN	Tranexamic Acid Effect on Platelet Aggregation Following Infant Cardiopulmonary Bypass
NCT02527811	PHASE4	UNKNOWN	Ulinastatin Injection in in Pediatric Patients Undergoing Open Heart Surgery
NCT03014700	PHASE4	COMPLETED	Fibrinogen Concentrate vs Cryoprecipitate
NCT03408340	PHASE4	TERMINATED	Paravertebral Nerve Blocks in Neonates
NCT03630796	PHASE4	UNKNOWN	Effect of Sevoflurane in Postoperative Troponin I Levels in Children Undergoing Congenital Heart Defects Surgery
NCT03667703	PHASE4	COMPLETED	Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease
NCT04453761	PHASE4	UNKNOWN	Thiamine Influenced on Substrate Energy Effectiveness in Indonesian Children Undergoing Cardiopulmonary Bypass
NCT06668389	PHASE4	RECRUITING	Sodium-Glucose Cotransporter 2 Inhibitors for Repaired Tetralogy of Fallot Patients for Enhancement of Cardio-Pulmonary Status Trial
NCT07499154	PHASE4	NOT_YET_RECRUITING	Perioperative Lidocaine for Lung Protection in Infants Undergoing Cardiac Surgery
NCT00000470	PHASE3	COMPLETED	Infant Heart Surgery: Central Nervous System Sequelae of Circulatory Arrest
NCT00000494	PHASE3	COMPLETED	Management of Patent Ductus in Premature Infants
NCT01134302	PHASE3	UNKNOWN	Hybrid Versus Norwood Management Strategies in Infants Undergoing Single Ventricle Palliation
NCT01607983	PHASE3	WITHDRAWN	Effects of Pulmonary Vasodilation Upon VA Coupling in Fontan Patients
NCT01662011	PHASE3	UNKNOWN	Application of Neurally Adjusted Ventilatory Assist to Children After Congenital Cardiac Surgery
NCT02320669	PHASE3	COMPLETED	Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass
NCT02615262	PHASE3	COMPLETED	Intraoperative Dexamethasone in Pediatric Cardiac Surgery
NCT03153137	PHASE3	COMPLETED	Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects
NCT03154476	PHASE3	COMPLETED	Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study
NCT04536194	PHASE3	COMPLETED	Dopamine Versus Norepinephrine Under General Anesthesia
NCT04702373	PHASE3	ACTIVE_NOT_RECRUITING	Training in Exercise Activities and Motion for Growth (TEAM 4 Growth) RCT
NCT05049590	PHASE3	COMPLETED	Acute Normovolemic Hemodilution in Complex Cardiac Surgery
NCT06406517	PHASE3	UNKNOWN	Comparative Effectiveness of Gadopiclenol for Evaluation of Adult Congenital Heart Anatomy and Hemodynamics
NCT06693674	PHASE3	RECRUITING	Effect of Sacubitril-Valsartan on Cardiac Structure and Function
NCT06955260	PHASE3	NOT_YET_RECRUITING	SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure
NCT00115375	PHASE2	COMPLETED	Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
NCT00350220	PHASE2	COMPLETED	Transfusion Strategies in Pediatric Cardiothoracic Surgery
NCT00374088	PHASE2	COMPLETED	N-Acetylcysteine in Neonatal Congenital Heart Surgery (INACT Study)
NCT00538785	PHASE2	COMPLETED	A Study to Evaluate MEDI-524 In Children With Hemodynamically Significant Congenital Heart Disease
NCT00770705	PHASE2	WITHDRAWN	Parenteral Phenoxybenzamine During Congenital Heart Disease Surgery
NCT00919945	PHASE2	TERMINATED	Impact of Early Enteral Feeding on Splanchnic Blood Flow After Surgery for Critical Heart Disease in the Newborn
NCT01063712	PHASE2	COMPLETED	Safety and Effectiveness of the Device Nit-Occlud® PDA-R
NCT01069510	PHASE2	COMPLETED	Spironolactone in Adult Congenital Heart Disease
NCT01189981	PHASE2	COMPLETED	Effect of eHealth Encouragements to Intensive Exercise in Adolescents With Congenital Heart Disease
NCT01330433	PHASE2	COMPLETED	Effects of CoSeal on Bleeding & Adhesions in Pediatric Heart Surgery
NCT01662037	PHASE2	COMPLETED	Bosentan Therapy in Children With Functional Single Ventricle
NCT01668264	PHASE2	UNKNOWN	Imaging Assessment of Diastolic Function
NCT01827059	PHASE2	UNKNOWN	Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE